US-based pharmaceutical company Bristol-Myers Squibb has completed the $280m expansion of its biologics facility at Devens, Massachusetts.
The expansion project adds two new buildings to the existing 89 acre Devens facility and is designed to enhance the company’s presence in biologics medicines.
The two new constructions include the development of a Clinical Manufacturing Building and the Biologics Development Building.
The company will manufacture its investigational medicines used to support clinical trials at its Clinical Manufacturing Building, while the other building will be used for designing processes for the early production of investigational medicines.
Bristol-Myers Squibb global manufacturing and supply president Lou Schmukler said: "Biologics are increasingly important in the treatment of serious diseases and a rapidly growing part of our company’s pipeline of potential new therapies.
"Bringing together biologics development along with clinical and commercial manufacturing on one campus will help accelerate the development of these innovative medicines for patients worldwide."
The completion of the expansion is expected to generate an opportunity of an additional 200 jobs, which will eventually rise to nearly 350.
The new buildings cover an area of 200,000ft² and will add to the existing 600,000ft² complex comprising eight main buildings.
With the expansion, the company will add its total investment at the Devens site to more than $1bn.
There are pedestrian bridges built to connect the different buildings at the complex.
Image: The expansion project adds two new buildings to the existing biologics facility at Devens. Photo: courtesy of Business Wire.